Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q3 2023 · 10-Q
Revenue$61.49M$61.49M+66.1% vs Q3 2022 Net Income-$6.91M-$6.91MN/M vs Q3 2022 EPS Diluted-$0.26-$0.26N/M vs Q3 2022 Operating Income-$9,640,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,557,000N/M Margins · derivedOperating margin-15.7%+42.5 pt vs Q3 2022
Net margin-11.2%+43.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end